{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033145","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.498966+00:00","generated_at":"2026-06-04T13:17:56.494126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Synlogic discontinues PKU program; Q4 net loss $14.5M, cash $47.7M","bullets":["Discontinued Synpheny-3 pivotal study of SYNB1934 for PKU; evaluating strategic options.","Q4 2023 revenue $2.8M (vs $0.1M prior year) from Roche collaboration.","Q4 net loss $14.5M ($1.71 per share) vs $16.7M ($3.54 per share) prior year.","Full year 2023 net loss $57.3M ($8.81 per share) vs $66.1M ($13.83) prior year.","Cash and equivalents $47.7M as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033145","json":"https://secwatch.observer/filing/0000950170-24-033145.json","markdown":"https://secwatch.observer/filing/0000950170-24-033145.md","text":"https://secwatch.observer/filing/0000950170-24-033145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/sybx-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:17:56.494126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d20ce7da473985160a478d121daec34d8380a22","claim":"SYNLOGIC, INC. reported the year ended December 31, 2023 results: revenue $3.4 million, net income $57.3 million, EPS $8.81 per share.","evidence_excerpt":"$1.71 per share, compared to a consolidated net loss of $16.7 million, or $3.54 per share, for the corresponding period in 2022. Full Year 2023 Financial Results Revenues were $3.4 million for the year ended December 31, 2023, compared to $1.2 million for the same period in 2022. Revenue in both periods was associated with the research collaboration with Roche.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$3.4 million"},{"label":"Net income","value":"$57.3 million"},{"label":"EPS","value":"$8.81 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c6828d92174bf3a6db70429d92dde4618cff791b","claim":"SYNLOGIC, INC. reported the quarter ended December 31, 2023 results: revenue $2.8 million, net income $14.5 million, EPS $1.71 per share.","evidence_excerpt":"Company. Fourth Quarter 2023 Financial Results As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million. Revenue was $2.8 million for the three months ended December 31, 2023, compared to $0.1 million for the corresponding period in 2022. Revenue in both periods was associated with the research","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$2.8 million"},{"label":"Net income","value":"$14.5 million"},{"label":"EPS","value":"$1.71 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}